Bookmark Article
The FDA approved the first new class of antibiotics for treating urinary tract infections in nearly 30 years, with GSK’s pill Blujepa targeting E. coli bacteria resistant to standard antibiotics. UTIs are common and can lead to complications if untreated, making new treatment options crucial. Blujepa was successful in clinical trials and is expected to be available later this year, although the cost may be higher than generic options.
Full Article
